Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per share was 7.8% above analysts’ consensus ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported fourth-quarter earnings of $917.7 million. On a per-share basis, the Tarrytown, New York ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...

We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per ...